<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39375207</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">awae215</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awae215</ELocationID><Abstract><AbstractText>Post-mortem studies have shown that patients dying from severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection frequently have pathological changes in their CNS, particularly in the brainstem. Many of these changes are proposed to result from para-infectious and/or post-infection immune responses. Clinical symptoms such as fatigue, breathlessness, and chest pain are frequently reported in post-hospitalized coronavirus disease 2019 (COVID-19) patients. We propose that these symptoms are in part due to damage to key neuromodulatory brainstem nuclei. While brainstem involvement has been demonstrated in the acute phase of the illness, the evidence of long-term brainstem change on MRI is inconclusive. We therefore used ultra-high field (7 T) quantitative susceptibility mapping (QSM) to test the hypothesis that brainstem abnormalities persist in post-COVID patients and that these are associated with persistence of key symptoms. We used 7 T QSM data from 30 patients, scanned 93-548 days after hospital admission for COVID-19 and compared them to 51 age-matched controls without prior history of COVID-19 infection. We correlated the patients' QSM signals with disease severity (duration of hospital admission and COVID-19 severity scale), inflammatory response during the acute illness (C-reactive protein, D-dimer and platelet levels), functional recovery (modified Rankin scale), depression (Patient Health Questionnaire-9) and anxiety (Generalized Anxiety Disorder-7). In COVID-19 survivors, the MR susceptibility increased in the medulla, pons and midbrain regions of the brainstem. Specifically, there was increased susceptibility in the inferior medullary reticular formation and the raphe pallidus and obscurus. In these regions, patients with higher tissue susceptibility had worse acute disease severity, higher acute inflammatory markers, and significantly worse functional recovery. This study contributes to understanding the long-term effects of COVID-19 and recovery. Using non-invasive ultra-high field 7 T MRI, we show evidence of brainstem pathophysiological changes associated with inflammatory processes in post-hospitalized COVID-19 survivors.</AbstractText><CopyrightInformation>Â© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rua</LastName><ForeName>Catarina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wolfson Brain Imaging Centre, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Cambridge Centre for Parkinson-plus, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Invicro, Invicro London, Burlington Danes Building, Imperial College London, London W12 0NN, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Betty</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1239-9608</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Radcliffe Department of Medicine and Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodgers</LastName><ForeName>Christopher T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Wolfson Brain Imaging Centre, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newcombe</LastName><ForeName>Virginia F J</ForeName><Initials>VFJ</Initials><Identifier Source="ORCID">0000-0001-6044-9035</Identifier><AffiliationInfo><Affiliation>Wolfson Brain Imaging Centre, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Anaesthesia, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manktelow</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Anaesthesia, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatfield</LastName><ForeName>Doris A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Division of Anaesthesia, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawcer</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Outtrim</LastName><ForeName>Joanne G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Division of Anaesthesia, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lupson</LastName><ForeName>Victoria C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Wolfson Brain Imaging Centre, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamatakis</LastName><ForeName>Emmanuel A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0001-6955-9601</Identifier><AffiliationInfo><Affiliation>Wolfson Brain Imaging Centre, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Anaesthesia, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Guy B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Wolfson Brain Imaging Centre, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>William T</ForeName><Initials>WT</Initials><Identifier Source="ORCID">0000-0001-7159-7025</Identifier><AffiliationInfo><Affiliation>Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezra</LastName><ForeName>Martyn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Rory</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clare</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cassar</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Radcliffe Department of Medicine and Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neubauer</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9017-5645</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Radcliffe Department of Medicine and Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ersche</LastName><ForeName>Karen D</ForeName><Initials>KD</Initials><Identifier Source="ORCID">0000-0002-3203-1878</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, Heidelberg 69115, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bullmore</LastName><ForeName>Edward T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Wolfson Brain Imaging Centre, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>David K</ForeName><Initials>DK</Initials><Identifier Source="ORCID">0000-0002-3228-9692</Identifier><AffiliationInfo><Affiliation>Wolfson Brain Imaging Centre, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Anaesthesia, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pattinson</LastName><ForeName>Kyle</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>University of Cambridge Centre for Parkinson-plus, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Council Cognition and Brain Sciences Unit, Cambridge CB2 7EF, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cambridge NeuroCOVID Group, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CITIID-NIHR COVID-19 BioResource Collaboration, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Radcliffe Department of Medicine and Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford OX3 9DU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DA, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NIHR203312</GrantID><Agency>NIHR Cambridge Biomedical Research Centre</Agency><Country /></Grant><Grant><GrantID>BRC-1215-20008</GrantID><Agency>NIHR Oxford Biomedical Research Centre</Agency><Country /></Grant><Grant><GrantID>0009118</GrantID><Agency>University of Oxford Medical Sciences Division COVID-19 Research Response Fund</Agency><Country /></Grant><Grant><GrantID>103838</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00030/14</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Academy of Medical Sciences/The Health Foundation Clinician Scientist Fellowship</Agency><Country /></Grant><Grant><Agency>NIHR</Agency><Country /></Grant><Grant><Agency>BHF Centre of Research Excellence, Oxford</Agency><Country /></Grant><Grant><Agency>Cambridge Centre for Parkinson-Plus</Agency><Country /></Grant><Grant><GrantID>NIHR203316</GrantID><Agency>NIHR Oxford Health Biomedical Research Centre</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Brain. 2024 Oct 28:awae332. doi: 10.1093/brain/awae332</RefSource><PMID Version="1">39468699</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">7T MRI</Keyword><Keyword MajorTopicYN="N">brainstem</Keyword><Keyword MajorTopicYN="N">coronavirus disease of 2019</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">quantitative susceptibility mapping</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>23</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39375207</ArticleId><ArticleId IdType="doi">10.1093/brain/awae215</ArticleId><ArticleId IdType="pii">7811070</ArticleId></ArticleIdList></PubmedData></PubmedArticle>